Effect of lignocaine on arginine-vasopressin plasma levels: baseline or induced by frusemide.
1. To assess whether or not lignocaine influences baseline and frusemide-induced (5 mg kg-1) plasma concentrations of arginine-vasopressin (AVP), 2 groups of rabbits received an infusion of lignocaine (130 micrograms min-1 kg-1) for 6 h. Lignocaine-induced changes in AVP plasma concentrations were substantiated by measurement of diuresis and natriuresis and hepatic plasma flow, by means of an infusion of indocyanine green (ICG) (249 micrograms min-1 kg-1). 2. Baseline plasma AVP levels were 4.9 +/- 0.9 pg ml-1 (+/- s.e.), and following lignocaine, these values were reduced to 0.7 +/- 0.1 pg ml-1 (P less than 0.01). Frusemide increased AVP levels to 134.1 +/- 73.6 pg ml-1 (P less than 0.05) and lignocaine totally prevented this increase, e.g. mean AVP levels of 2.7 pg ml-1. 3. Lignocaine enhanced baseline diuresis secondary to an increase in free water clearance; none of the experimental conditions affected the diuresis and natriuresis induced by frusemide. 4. Frusemide reduced the hepatic plasma flow and this decrease was not reversed by the infusion of lignocaine. 5. It is concluded that in healthy rabbits lignocaine reduces baseline secretion of AVP and its antidiuretic effect; in addition, lignocaine prevents the rise in AVP induced by frusemide.
Gariépy
L
L
Department of Pharmacology, Faculty of Medicine, University of Montréal, Québec, Canada.
Larose
P
P
Bailey
B
B
du Souich
P
P
D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood* / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects; D005665:Furosemide / Q000494:pharmacology*; D066298:In Vitro Techniques; D007208:Indocyanine Green; D008012:Lidocaine / Q000493:pharmacokinetics / Q000494:pharmacology*; D008102:Liver Circulation / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D011817:Rabbits
D001127:Arginine Vasopressin; D005665:Furosemide; D008012:Lidocaine; D007208:Indocyanine Green